Clinical trial
Bortezomib With or Without Gemcitabine in Treating Patients With Metastatic…
NCT00052689 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00052689 |
|---|---|
| Title | Bortezomib With or Without Gemcitabine in Treating Patients With Metastatic Pancreatic Cancer |
| Official title | A Randomized Phase II Trial of PS-341 and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Duct Cell Adenocarcinoma of the Pancreas, Stage IV Pancreatic Cancer |
| Intervention type | Drug |
| Interventions | bortezomib, gemcitabine hydrochloride |
| Enrollment | 88 |
| Start date | Dec 1, 2002 |
| Primary completion | Oct 1, 2007 |
| First posted | Jan 27, 2003 |
| Last update posted | Oct 8, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: